Currently, PD-1/PD-L1 monoclonal antibodies have been developed as immune checkpoint inhibitors for cancer therapy to remove the “brake” on the immune system and restore the ability of T cells to attack tumor cells (15). This evidence concerns the gene CD274 and neoplasm.